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Abstract: Botulinum toxin type A injections are one of the most popular cosmetic procedures 
for diminishing the appearance of facial lines caused by habitual facial muscle contractions. 
Although the manufacturer’s labeling recommends botulinum toxin only for the treatment of 
glabellar lines among adults younger than 65 years of age, there is widespread use of the toxin 
for other cosmetic purposes and for patients who may be older than 65. Evidence-based safety 
and efﬁ  cacy data on botulinum toxin use in elderly patients is limited. However, given the age-
related skin changes and multifactorial causes of wrinkles in the elderly, as well as the higher 
risk for potential side effects due to concomitant diseases and medications, a careful risk-beneﬁ  t 
assessment should precede the decision to use botulinum toxin in the elderly patient. 
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Introduction
Injections of botulinum toxin type A (BTX-A, Botox Cosmetic, Allergan Inc, CA, USA) 
have become one of the most popular cosmetic procedures worldwide (Pitman 2005). 
In the US, more than 2.2 million cosmetic injections were reported in 2003, only a 
year after it received Food and Drug Administration (FDA) approval for treatment of 
glabellar lines (Batra et al 2005). Today it is the most common cosmetic procedure 
performed in the US (Wise and Greco 2006). In contrast to other products used for 
cosmetic procedures, BTX-A is minimally invasive, relatively easy and quick to ad-
minister, has a relatively immediate and noticeable effect and a quick recovery period, 
and is often more affordable than other cosmetic treatments (Klein 2004). Alternative 
procedures involve the use of injectable ﬁ  llers (eg, silicone, collagen), resurfacing 
techniques (eg, dermabrasion, chemical peels, laser resurfacing), and surgery, which 
may lead to serious and permanent adverse effects, eg, photosensitivity, scarring, 
surgical morbidity, and involve a long recovery period (Lemperle et al 2001; Cather 
et al 2002). 
BTX-A is a neuromuscular blocking agent that works by producing transient, 
dose-dependent, focal weakening of the facial muscles involved in expressions that 
lead to a tired, disapproving or aged look, such as frowning or wrinkling the forehead 
(Klein 2004; Carruthers et al 2004). The ideal candidates for BTX-A injections are 
men and women between 40 and 60 years of age whose facial wrinkles are primarily 
caused by repeated, habitual muscle contraction over time (Allergan PI 2005). Despite 
the manufacturer’s labeling for the use of BTX-A in adults younger than 65 years 
of age, there have been anecdotal reports of BTX-A use in older patients. However, 
there is little published information on the efﬁ  cacy and safety of BTX-A for cosmetic 
reasons in this population.  
Prior to its use for cosmetic reasons, local injections of BTX-A were successful in 
treating other disorders characterized by inappropriate and excessive muscle contrac-
tion, such as dystonia, blepharospasm, and spasticity (Cote et al 2005).Clinical Interventions in Aging 2007:2(1) 82
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BTX-A is one of eight potent botulinum toxin serotypes pro-
duced by the bacteria Clostridia botulinum, a Gram-positive 
spore-forming anaerobe. Commercially available BTX-A 
is a puriﬁ  ed and diluted form of the neurotoxin. Following 
injection into a muscle, BTX-A binds to the presynaptic nerve 
terminal and selectively blocks the release of acetylcholine at 
the neuromuscular junction, thereby preventing muscle con-
traction. The effect is temporary and reversible following the 
sprouting of new axons and development of extrajunctional 
acetylcholine receptors over time. Motor function is typically 
restored in approximately 3–6 months. Acetylcholine syn-
thesis and storage are not affected (Frampton and Easthope 
2003; Klein 2004; Allergan PI 2005).
BTX-A is most effective for wrinkles that form because of 
muscle contraction, where weakening of the muscle smoothes 
and ﬂ  attens the overlying skin. After a BTX-A injection, an 
improvement in appearance occurs within 1 to 14 days, peaks 
at approximately 4 weeks, and begins wearing off after 10–12 
weeks; therefore, a repeat injection approximately every 3–4 
months is necessary to maintain the cosmetic effect of BTX-
A (Klein 2004; Allergan PI 2005). BTX-A is not effective 
for facial wrinkles caused by mechanisms other than muscle 
contraction, such as sun damage, environmental pollutants, 
or subcutaneous soft tissue atrophy.
Because BTX preparations vary in potency, commercially 
available botulinum toxins, including Botox Cosmetic, Dys-
port (Ispen LTD, Slough, UK), and Myobloc (Elan Pharmaceu-
ticals, San Francisco, CA, USA), are not interchangeable.
Uses
Cosmetic uses for botulinum toxin include treating the verti-
cal lines between the eyebrows (glabellar lines) and on the 
bridge of the nose, squint lines or crows feet at the corners 
of the eyes, forehead horizontal lines, periorbital lines and 
nasolabial folds around the mouth, and the thick platysmal 
bands around the neck, also known as “turkey neck” (Blitzer 
and Binder 2002; Carruthers et al 2004; Klein 2005). The 
recommended dose for glabellar lines is 20 units distributed 
among 5 injection sites; however, the dosing is often indi-
vidualized according to the location and size of the muscle 
as well as the depth of the wrinkle. The BTX-A doses used 
for cosmetic purposes are much lower than those used in 
therapeutic cases (Allergan PI 2005). 
Considerations in the elderly
It is difﬁ  cult to tell for sure whether patients over the age 
of 65 respond differently to BTX-A than younger patients; 
there have been no studies investigating cosmetic uses of 
BTX-A speciﬁ  cally in the elderly, and there have not been 
enough elderly patients enrolled in clinical studies to make 
any meaningful comparisons (Allergan PI 2005). However, 
since the elderly are more likely to have thinner and less 
elastic skin, weaker facial muscles, and wrinkles that over 
time are caused by gravity-induced tissue sagging rather than 
muscle contraction, the elderly are not expected to respond 
as well to BTX-A treatment (Norman 2003; Rhodes et al 
2003). BTX-A may help soften wrinkles that are noticeable 
even without muscle contraction, but additional resurfacing 
procedures are often needed to lead to visible differences in 
the appearance of the wrinkle (Patel et al 2004). 
The site of injection also warrants special considerations 
in the elderly. Treatment of forehead lines, for example, 
would require injections to the frontalis muscle, which many 
older people use to raise their eyebrows and eyelids to see. 
Older patients may also have extra skin under the brow 
(pseudoptosis) which could be worsened by BTX-A treat-
ment. Older patients who receive BTX-A for glabellar lines 
may be more at risk for complications such as eyelid ptosis 
if they have a reduced or absent orbital septum (Fagien 2003; 
Klein 2004; Carruthers et al 2004).
Because of their delicate skin, older patients are also more 
susceptible to bruising from BTX-A injections. The risk for 
bruising is even greater among patients taking medications 
that inhibit clotting, such as vitamin E, aspirin, nonsteroidal 
antiinﬂ  ammatory drugs, and herbal products such as ginseng, 
ginko biloba, and garlic. Many physicians advise avoiding 
these medications and products 10–14 days prior to treatment. 
A full medication and supplement history should be obtained 
from all patients prior to receiving BTX-A. This is particu-
larly important for elderly patients, who are more likely to 
be taking multiple medications or supplements (Rhodes et al 
2003; Klein 2004; McLean and Le Couteur 2004). 
Conservative dosing, injection of low volumes, and 
proper placement of the injection can reduce the possibility of 
spread of the toxin to unintended muscles. Electromyographic 
guidance may be helpful in selecting the appropriate muscles 
for injection (Klein 2004; Carruthers et al 2004; Vartanian 
and Dayan 2005). The manufacturer recommends starting 
at the lowest possible effective dose for elderly patients 
(Allergan PI 2005).
Safety
The most common side effects are related to the injection 
technique and include local redness, bruising, swelling, and 
mild pain (Allergan PI 2005). These side effects can be Neuropsychiatric Disease and Treatment 2007:3(1) 83
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reduced by using proper injection techniques and conser-
vative dosing. Patients who have severe wrinkles (which 
require a higher dose of BTX-A) or who have altered facial 
anatomy, and those with pre-existing neuromuscular disease 
are more at risk for complications. Other side effects include 
eyelid ptosis, focal facial weakness, and headache. Serious 
adverse events included dysphagia, ﬂ  u-like symptoms, and 
hypersensitivity reactions. Complications that result from 
weakened muscles adjacent to the injection site are due to 
the diffusion of toxin to unintended muscles; this may be 
minimized through proper injection technique (Klein 2004; 
Naumann and Jankovic 2004; Batra et al 2005; Vartanian 
and Dayan 2005). 
Topical anesthetics applied prior to injection, use 
of smaller gauge needles, slow injection, small doses, 
and application of ice immediately after injection can help 
minimize pain and discomfort following BTX-A injections. 
Many physicians encourage patients to remain upright for 
3–4 hours after the procedure, avoid massaging the treatment 
area, and actively contract the injected muscle to encourage 
the uptake of toxin by the intended muscles (Carruthers and 
Carruthers 1998; Carruthers et al 2004; Klein 2004). 
Proper dilution, storage, and handling of BTX-A are also 
essential for minimizing adverse outcomes (Cote et al 2005).
BTX-A should not be used in patients who are pregnant, 
nursing, or have neuromuscular disease. Patients taking medi-
cations that could potentiate the effects of BTX-A should 
also not receive BTX-A. Examples of these medications 
include aminoglycosides, quinidine, and anticholinesterases. 
BTX-A is also contraindicated in the presence of infection 
or inﬂ  ammation at the injection site and in patients with 
known hypersensitivity to BTX-A or any ingredient in the 
formulation (Allergan PI 2005).
Reports of serious cardiovascular events, includ-
ing arrhythmias, have been reported in post-marketing 
surveillance of adverse events related to the cosmetic 
uses of BTX-A. The incidence was 2.8% (1/36) for seri-
ous arrhythmia and 5.6% (2/36) for any serious cardiovascu-
lar event. In many of these cases the patients had preexisting 
cardiovascular risk factors that may have been related to 
the adverse event. Nevertheless, BTX-A should be used 
with caution in patients with cardiovascular comorbidities, 
which are more common among the elderly (Wenge 2000; 
Cote et al 2005).
Conclusion
Physicians should consider the suitability of BTX-A for 
elderly patients, taking into account the etiology of their 
wrinkles, skin fragility, facial anatomy, concomitant medi-
cations and medical conditions, risk of adverse effects and 
the likelihood of treatment beneﬁ  t. Although BTX-A has 
a low perceived risk of side effects, older patients may be 
more susceptible to these effects. The beneﬁ  t from BTX-A 
treatment is also questionable since wrinkles in older people 
are more likely to be caused by factors other than repeated 
muscle contraction. Precautions such as a obtaining a full 
medication and medical history, beginning with low doses, 
and proper injection technique are especially important for 
optimal outcomes in elderly patients who are deemed to be 
good candidates for BTX-A cosmetic injections.
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